Market Dynamics
The German market for rapid influenza diagnostic tests is forecast to experience significant growth over the upcoming years due to the prevalence of the influenza virus and rising global awareness of preventative healthcare. This market was valued at $xxx million in 2018, and is expected to record a CAGR of xx% during the period 2018 to 2032. An increase in the prevalence of influenza is driving the growth of the market, as more people are becoming aware of the risk of contracting the virus and are running diagnostics to ensure they are not infected. This has led to more rapid diagnostics kits being used, as they can give a quick and accurate result to enable timely treatment and avoid the virus spreading further. Alongside this, the rising promotion of personal hygiene practices and growing patient awareness provide additional impetus to the market. In addition, government initiatives to enhance access to healthcare services are also contributing to the demand, as more people can now get access to quick and accurate diagnosis. This trend is set to continue as more people learn about the benefits of using rapid influenza diagnostics tests.
Furthermore, developments in product technology have led to more rapid and accurate diagnostic test kits that can identify the presence of influenza in people more swiftly with fewer mistakes. For instance, the advent of the reverse transcription-polymerase chain reaction (RT-PCR) method has enabled rapid detection of the virus in saliva, mucosal swabs or bronchial alveolar lavage fluid (BALF). The introduction of more advanced technology has also made the test kits more affordable, as they no longer require laboratory back-up, making them much more cost-efficient. This has helped to widen the reach of diagnostic testing and subsequently the market is expected to benefit in the coming years. All of these factors are expected to positively affect the demand for rapid influenza diagnostic tests in Germany and drive the growth of the market over the next few years. However, the market is expected to face certain restraints such as the low reimbursement rate for the tests, the availability of alternate diagnostic tests and the high cost associated with the test kits.
